TW434018B - Pharmaceutical composition for treating chronic progressive vascular diseases - Google Patents

Pharmaceutical composition for treating chronic progressive vascular diseases Download PDF

Info

Publication number
TW434018B
TW434018B TW085109390A TW85109390A TW434018B TW 434018 B TW434018 B TW 434018B TW 085109390 A TW085109390 A TW 085109390A TW 85109390 A TW85109390 A TW 85109390A TW 434018 B TW434018 B TW 434018B
Authority
TW
Taiwan
Prior art keywords
pps
disease
patent application
composition
scope
Prior art date
Application number
TW085109390A
Other languages
English (en)
Chinese (zh)
Inventor
Gary E Striker
Liliane J Striker
Fred P Sherman
Original Assignee
Baker Norton Pharma
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma, Us Health filed Critical Baker Norton Pharma
Application granted granted Critical
Publication of TW434018B publication Critical patent/TW434018B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW085109390A 1995-06-07 1996-08-03 Pharmaceutical composition for treating chronic progressive vascular diseases TW434018B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/478,347 US5643892A (en) 1995-06-07 1995-06-07 Method of treating chronic progressive vascular diseases
BR9704114-9A BR9704114A (pt) 1995-06-07 1997-07-28 Processo de tratamento de doenças vasculares progressivas crÈnicas

Publications (1)

Publication Number Publication Date
TW434018B true TW434018B (en) 2001-05-16

Family

ID=25664870

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085109390A TW434018B (en) 1995-06-07 1996-08-03 Pharmaceutical composition for treating chronic progressive vascular diseases

Country Status (14)

Country Link
US (1) US5643892A (fr)
EP (1) EP0809505B1 (fr)
AU (1) AU699012B2 (fr)
BR (1) BR9704114A (fr)
CA (1) CA2210351C (fr)
DE (1) DE809505T1 (fr)
ES (1) ES2115571T3 (fr)
HU (1) HUP9802431A3 (fr)
IL (1) IL121217A (fr)
NO (1) NO313686B1 (fr)
NZ (1) NZ309991A (fr)
TW (1) TW434018B (fr)
WO (1) WO1996040158A1 (fr)
ZA (1) ZA964247B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010005720A1 (en) * 1995-06-07 2001-06-28 U.S.A. As Represented By The Secretary Department Of Health And Human Services Method of treating chronic progressive vascular scarring diseases
US6255295B1 (en) 1996-12-23 2001-07-03 Nutramax Laboratories, Inc. Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
UA65587C2 (en) 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
DE19747195A1 (de) * 1997-10-24 1999-04-29 Knoll Ag Verwendung von Glykosaminoglykanen zur Herstellung von pharmazeutischen Zubereitungen zur Behandlung von mit Diabetes assoziierten Augenkrankheiten
WO2001052867A1 (fr) 2000-01-19 2001-07-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Utilisation de polysulfate de pentosan pour le traitement de certains troubles de la prostate
US20080214480A1 (en) * 2005-07-22 2008-09-04 Trf Pharma, Inc. Method for Treating Sickle Cell Disease and Sickle Cell Disease Sequalae
WO2007123800A2 (fr) * 2006-04-03 2007-11-01 Nutramax Laboratories, Inc. Formulations de polysulfate de pentosane stabilisé (pps) et procédés d'analyse de ces dernières
WO2010103837A1 (fr) 2009-03-11 2010-09-16 ゼライス株式会社 Inhibiteur de progression ou agent prophylactique pour l'athérosclérose, agent d'abaissement du niveau sanguin de cholestérol et produit alimentaire fonctionnel ou produit alimentaire pour des utilisations spécifiques pour la santé
WO2011088418A2 (fr) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition par le polysulfate de pentosane de l'activation de nfkb induite par le tnf-alpha
ES2664844T3 (es) 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
US20130273096A1 (en) * 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
JP6935960B2 (ja) 2018-08-20 2021-09-15 株式会社レクメド 新規ポリ硫酸ペントサンナトリウム製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966890A (en) * 1986-04-04 1990-10-30 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
DE3725554A1 (de) * 1987-08-01 1989-02-09 Hoechst Ag Pharmazeutisches kombinationspraeparat sowie dessen herstellung und verwendung
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate

Also Published As

Publication number Publication date
HUP9802431A2 (hu) 1999-02-01
IL121217A (en) 2000-09-28
ZA964247B (en) 1996-12-04
EP0809505A1 (fr) 1997-12-03
NO973081L (no) 1997-08-27
ES2115571T1 (es) 1998-07-01
DE809505T1 (de) 1998-05-28
NO313686B1 (no) 2002-11-18
AU6030096A (en) 1996-12-30
EP0809505B1 (fr) 2003-04-02
IL121217A0 (en) 1999-10-28
US5643892A (en) 1997-07-01
AU699012B2 (en) 1998-11-19
NO973081D0 (no) 1997-07-02
BR9704114A (pt) 2000-06-06
CA2210351C (fr) 2003-09-23
ES2115571T3 (es) 2003-09-01
WO1996040158A1 (fr) 1996-12-19
HUP9802431A3 (en) 2001-06-28
EP0809505A4 (fr) 1998-07-01
NZ309991A (en) 2001-03-30
CA2210351A1 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
TW403656B (en) Pharmaceutical anti-tnf antibodies compositions comprising for the treatment of disorders with an elevated serum level of interleukin-6
Luo et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide
Martinet et al. Differential expression of the tumor necrosis factor/cachectin gene by blood and lung mononuclear phagocytes
Jeyaseelan et al. Induction of CXCL5 during inflammation in the rodent lung involves activation of alveolar epithelium
TW434018B (en) Pharmaceutical composition for treating chronic progressive vascular diseases
Matsumoto et al. Difference in ceramide composition between" dry" and" normal" skin in patients with atopic dermatitis.
Speiser et al. TNF receptor p55 controls early acute graft-versus-host disease.
Gatti et al. Role of tumour necrosis factor and reactive oxygen intermediates in lipopolysaccharide‐induced pulmonary oedema and lethality
Chou et al. Apoptosis in rheumatoid arthritis–expression of Fas, Fas‐L, p53, and Bcl‐2 in rheumatoid synovial tissues
Tasker et al. Use of co-trimoxazole in chronic renal failure
KR101426689B1 (ko) Ｎｕｔｌｉｎ­３ａ 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
Chen et al. Effects of dexmedetomidine on immune cells: a narrative review
TW557213B (en) Pharmaceutical composition for treating chronic progressive vascular scarring diseases
WO2021073249A1 (fr) UTILISATION DE β-NMN DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT OU LA PRÉVENTION DE LÉSIONS D'ORGANE INDUITES PAR UNE SEPTICÉMIE
Uehara et al. Paternal and Maternal Atopic Dermatitis Have the Same Influence on Development of the Disease in Children.
US20210186944A1 (en) Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method
Winkelmann et al. Subcutaneous xanthogranulomatosis: an inflammatory non-X histiocytic syndrome (subcutaneous xanthomatosis)
WO2021213504A1 (fr) Utilisation d'un inhibiteur de vegf dans la préparation d'un médicament pour le traitement de maladies associées à l'hypoxie
CN118076369A (zh) Cd40l特异性tn3衍生支架及其用于治疗和预防类风湿性关节炎的方法
RU2196589C2 (ru) Способ индукции рассасывания образовавшихся рубцов или фиброзных образований в кровеносных сосудах или в сосудистой сети млекопитающего
Yoshida Herpetic pharyngitis with mammary and genital herpes due to sexual contact.
Koga et al. Syringocystadenoma Papilliferum without an Antecedent Naevus Sebaceous.
WO2022003439A1 (fr) Agents thérapeutiques pour le traitement et la prévention de maladies auto-immunes et du cancer et méthode de dépistage
Hervonen et al. Spiegler-Fendt Type Lymphocytoma Cutis: a Case Report of Two Patients Successfully Treated with Interferon Alpha-2b.
CN116535459A (zh) 一种酚酸类化合物及其合成方法、用途

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees